Literature DB >> 2071168

Biodegradable microparticles as controlled release antigen delivery systems.

D T O'Hagan1, D Rahman, J P McGee, H Jeffery, M C Davies, P Williams, S S Davis, S J Challacombe.   

Abstract

A model but poor immunogen, ovalbumin (OVA), was entrapped in a novel antigen delivery system comprising poly (D,L-lactide-co-glycolide) (PLGA) microparticles. Both the primary and the secondary IgG antibody responses obtained with OVA in microparticles were compared to those obtained with OVA emulsified in Freunds' adjuvants by two routes of immunization, intraperitoneal (i.p.) and subcutaneous (s.c.) injection. Following single i.p. or s.c. injections, the IgG serum antibody responses to OVA in microparticles were significantly greater than the responses to OVA in Freunds' complete adjuvant (FCA) for up to 10 weeks. After s.c. booster doses of OVA, the secondary IgG antibody responses to OVA in microparticles remained greater than the secondary responses to OVA in Freunds', but not significantly so. Furthermore, the primary IgG responses to OVA in microparticles obtained 8-12 weeks after a single i.p. injection were greater than the secondary responses to OVA in Freunds' obtained by repeat s.c. injections at Weeks 0 and 6. These results demonstrate that microparticles can function as potent antigen delivery systems for an entrapped antigen. Due to their ability to degrade slowly in vivo and to release entrapped antigens, microparticles have considerable potential as controlled release antigen delivery systems for the induction of long-term immune responses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2071168      PMCID: PMC1384472     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  7 in total

1.  Tissue response to biodegradable injectable microcapsules.

Authors:  G E Visscher; M A Robison; G J Argentieri
Journal:  J Biomater Appl       Date:  1987-07       Impact factor: 2.646

2.  Microparticles as potentially orally active immunological adjuvants.

Authors:  D T O'Hagan; K Palin; S S Davis; P Artursson; I Sjöholm
Journal:  Vaccine       Date:  1989-10       Impact factor: 3.641

3.  Vaccines for the Third World.

Authors:  B R Bloom
Journal:  Nature       Date:  1989-11-09       Impact factor: 49.962

4.  Antigen processing and presentation by macrophages.

Authors:  P M Allen; E R Unanue
Journal:  Am J Anat       Date:  1984-07

5.  Release of human serum albumin from poly(lactide-co-glycolide) microspheres.

Authors:  M S Hora; R K Rana; J H Nunberg; T R Tice; R M Gilley; M E Hudson
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

6.  A new long-acting injectable microcapsule system for the administration of progesterone.

Authors:  L R Beck; D R Cowsar; D H Lewis; R J Cosgrove; C T Riddle; S L Lowry; T Epperly
Journal:  Fertil Steril       Date:  1979-05       Impact factor: 7.329

7.  Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage.

Authors:  Y Tabata; Y Ikada
Journal:  Biomaterials       Date:  1988-07       Impact factor: 12.479

  7 in total
  39 in total

1.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 2.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

3.  Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.

Authors:  S J Challacombe; D Rahman; H Jeffery; S S Davis; D T O'Hagan
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

4.  Preparation and Characterization of Magnetic Nano-in-Microparticles for Pulmonary Delivery.

Authors:  Amber A McBride; Dominique N Price; Pavan Muttil
Journal:  Methods Mol Biol       Date:  2017

5.  Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.

Authors:  K J Maloy; A M Donachie; D T O'Hagan; A M Mowat
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

Review 6.  Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm?

Authors:  W C Koff; A M Schultz
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317

Review 7.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

8.  Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates.

Authors:  S B Periwal; T J Speaker; J J Cebra
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

9.  Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery.

Authors:  Brittany A Bailey; Kashappa-Goud H Desai; Lukasz J Ochyl; Susan M Ciotti; James J Moon; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2017-08-22       Impact factor: 4.939

Review 10.  Approaches for enhancing oral bioavailability of peptides and proteins.

Authors:  Jwala Renukuntla; Aswani Dutt Vadlapudi; Ashaben Patel; Sai H S Boddu; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-02-18       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.